Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
NCT ID: NCT01607203
Last Updated: 2015-02-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
120 participants
INTERVENTIONAL
2011-11-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles
NCT01390207
Trial Comparing hCG Triggering Versus GnRH Agonist Triggering in PCOS Patients
NCT01683513
Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
NCT00415792
Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
NCT01093443
Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)
NCT03307720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hCG
5000 IU Pregnyl SC
pregnyl
5000 IU SC
hCG and GnRH agonist
5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
Decapeptyl Daily
Decapeptyl 0.2 mg SC once 1day
pregnyl
5000 IU SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decapeptyl Daily
Decapeptyl 0.2 mg SC once 1day
pregnyl
5000 IU SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1,2 or 3 rd IVF-cycle
Exclusion Criteria
* patients with endocrinological diseases or problems
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Onze Lieve Vrouw Hospital
OTHER
AZ Jan Palfijn Gent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Decleer Wim
gynaecologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wim Decleer, gynacologist
Role: PRINCIPAL_INVESTIGATOR
IVF Centrum Jan Palfijn Gent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A Z Jan Palfijn
Ghent, Oost-vlaanderen, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dr. Decleer Wim
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.